Novasep announces major recapitalisation to boost growth

Published: 22-Mar-2012
Finance

New shareholders to support the group’s development going forward


Novasep, a French provider of manufacturing solutions to the life science industry, has completed a €310m recapitalisation, which includes funding from new and existing investors.

Fonds Stratégique d'Investissement (FSI), France’s strategic investment fund, has awarded the firm €30m and has become a shareholder.

Azulis, another French investment fund and historical investor in Novasep, has also invested €3m.

Novasep says it currently has more than €40m in cash available for financing growth projects.

  • Companies:
  • Axplora
See more

You may also like

Manufacturing

Novasep-PharmaZell invests €7.3M to increase API production capacity at Mourenx site

Read more
The initial priority will be to create a new pilot workshop for API production

Trending Articles

  1. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  2. Sales Account Manager - Print, Online and Event Sales - London - £38,000/yr - £40,000/yr This is an exciting role for an Account Manager to join the Science portfolio of HPCi Media. Please get in touch with alib@hpcimedia.com via email with a CV and covering letter
  3. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  4. SHL to expand Taiwan production facilities in US$40m investment To meet growing demand in the biologic injectable market
  5. Get ahead of the curve with a subscription Keep abreast of significant pharmaceutical developments around the world

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Novasep-PharmaZell invests €7.3M to increase API production capacity at Mourenx site

The initial priority will be to create a new pilot workshop for API production
Manufacturing

PharmaZell and Novasep announce CDMO merger

Dr Sylke Hassel, former CEO of PharmaZell, will be CEO of the merged group
Manufacturing

Novasep invests in HPAPI production capacity at Le Mans

Through optimisations to its manufacturing processes, the company says this workshop will offer production solutions with reduced environmental impact
Finance

Novasep invests to expand API production in France

Flow chemistry is one of Novasep's main current areas of focus, with the establishment of a research platform in flow chemistry at its Chasse-sur-Rhône site
Finance

Novasep invests $7.2m at Mourenx API manufacturing facility

The investment includes the installation of equipment and the revamping of cleanrooms for API isolation
Finance

Novasep expands Le Mans HPAPI manufacturing capacity

The company has been a partner to companies in the ADC arena for more than 15 years
Finance

Thermo Fisher acquires viral vector manufacturing business from Novasep

The business will be part of the pharma services business within the laboratory products and services segment
Subscribe now